Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

4 terminated/withdrawn out of 8 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 4

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 2(3)

Phase 4(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05347238Recruiting

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

Role: collaborator

NCT00557375Completed

Brain Tumor Treatment Satisfaction Survey

Role: lead

NCT03828058Phase 2Completed

Envarsus XL Immunosuppression Following Liver Transplantation

Role: lead

NCT01042574Phase 4Withdrawn

The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy

Role: lead

NCT00603824Phase 4Withdrawn

Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

Role: lead

NCT00548938Phase 2Terminated

Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM

Role: lead

NCT00376103Phase 1Terminated

Radiation Boost for Newly Diagnosed Glioblastoma Multiforme

Role: lead

NCT00589212Phase 2Completed

GliaSite 1-3 Mets Study

Role: collaborator

All 8 trials loaded